AVTX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of -49.65%. Avalo Therapeutics's return on equity of -375.96% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Avalo Therapeutics has a consensus price target of $31.33, signalling upside risk potential of 440.23%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 64.47%. Given that Avalo Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Avalo Therapeutics is more attractive than NovaBay Pharmaceuticals.

Avalo Therapeutics has a beta of 0.716, which suggesting that the stock is 28.421% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Avalo Therapeutics's net income of -$35.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of -2357.27%. Avalo Therapeutics's return on equity of -375.96% beat Palatin Technologies's return on equity of --.

Avalo Therapeutics has a consensus price target of $31.33, signalling upside risk potential of 440.23%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1268.52%. Given that Palatin Technologies has higher upside potential than Avalo Therapeutics, analysts believe Palatin Technologies is more attractive than Avalo Therapeutics.

Avalo Therapeutics has a beta of 0.716, which suggesting that the stock is 28.421% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are smaller than Palatin Technologies quarterly revenues of $350K. Avalo Therapeutics's net income of -$35.3M is lower than Palatin Technologies's net income of -$2.4M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of --. Avalo Therapeutics's return on equity of -375.96% beat Theriva Biologics's return on equity of --.

Avalo Therapeutics has a consensus price target of $31.33, signalling upside risk potential of 440.23%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 455.56%. Given that Theriva Biologics has higher upside potential than Avalo Therapeutics, analysts believe Theriva Biologics is more attractive than Avalo Therapeutics.

Avalo Therapeutics has a beta of 0.716, which suggesting that the stock is 28.421% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are larger than Theriva Biologics quarterly revenues of --. Avalo Therapeutics's net income of -$35.3M is lower than Theriva Biologics's net income of -$4.4M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of --. Avalo Therapeutics's return on equity of -375.96% beat Trevi Therapeutics's return on equity of --.

Avalo Therapeutics has a consensus price target of $31.33, signalling upside risk potential of 440.23%. On the other hand Trevi Therapeutics has an analysts' consensus of $19.83 which suggests that it could grow by 227.82%. Given that Avalo Therapeutics has higher upside potential than Trevi Therapeutics, analysts believe Avalo Therapeutics is more attractive than Trevi Therapeutics.

Avalo Therapeutics has a beta of 0.716, which suggesting that the stock is 28.421% less volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.406, suggesting its less volatile than the S&P 500 by 59.351%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are larger than Trevi Therapeutics quarterly revenues of --. Avalo Therapeutics's net income of -$35.3M is lower than Trevi Therapeutics's net income of -$11.4M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.